EE04589B1 - Processes and intermediates for the preparation of anticancer compounds - Google Patents

Processes and intermediates for the preparation of anticancer compounds

Info

Publication number
EE04589B1
EE04589B1 EEP200000255A EEP200000255A EE04589B1 EE 04589 B1 EE04589 B1 EE 04589B1 EE P200000255 A EEP200000255 A EE P200000255A EE P200000255 A EEP200000255 A EE P200000255A EE 04589 B1 EE04589 B1 EE 04589B1
Authority
EE
Estonia
Prior art keywords
intermediates
processes
preparation
anticancer compounds
anticancer
Prior art date
Application number
EEP200000255A
Other languages
Estonian (et)
Inventor
Shelton Lehner Richard
Norris Timothy
Paul Santafianos Dinos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000255A publication Critical patent/EE200000255A/en
Publication of EE04589B1 publication Critical patent/EE04589B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling
EEP200000255A 1999-03-31 2000-03-30 Processes and intermediates for the preparation of anticancer compounds EE04589B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (2)

Publication Number Publication Date
EE200000255A EE200000255A (en) 2000-12-15
EE04589B1 true EE04589B1 (en) 2006-02-15

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000255A EE04589B1 (en) 1999-03-31 2000-03-30 Processes and intermediates for the preparation of anticancer compounds

Country Status (50)

Country Link
US (1) US6476040B1 (en)
EP (1) EP1044969B1 (en)
JP (2) JP3420549B2 (en)
KR (2) KR100430210B1 (en)
CN (2) CN1215061C (en)
AP (2) AP1265A (en)
AR (1) AR018705A1 (en)
AT (1) ATE348098T1 (en)
AU (2) AU781402B2 (en)
BG (1) BG65194B1 (en)
BR (1) BRPI0001486B8 (en)
CA (2) CA2302965C (en)
CO (1) CO5160273A1 (en)
CR (1) CR6165A (en)
CZ (1) CZ299426B6 (en)
DE (1) DE60032275T2 (en)
DK (1) DK1044969T3 (en)
DZ (1) DZ3030A1 (en)
EA (3) EA005561B1 (en)
EE (1) EE04589B1 (en)
EG (1) EG22506A (en)
ES (1) ES2278578T3 (en)
GE (1) GEP20022653B (en)
GT (1) GT200000037A (en)
HK (1) HK1029790A1 (en)
HR (1) HRP20000182B1 (en)
HU (1) HU227698B1 (en)
ID (1) ID25427A (en)
IL (2) IL135245A0 (en)
IS (1) IS2468B (en)
MA (1) MA25087A1 (en)
MY (1) MY136270A (en)
NO (2) NO321952B1 (en)
NZ (2) NZ512818A (en)
OA (1) OA11335A (en)
PA (1) PA8491901A1 (en)
PE (1) PE20001599A1 (en)
PL (1) PL339330A1 (en)
PT (1) PT1044969E (en)
RS (1) RS49836B (en)
SG (2) SG121687A1 (en)
SK (1) SK287339B6 (en)
SV (1) SV2002000047A (en)
TN (1) TNSN00064A1 (en)
TR (1) TR200000837A2 (en)
TW (1) TW553939B (en)
UA (2) UA80955C2 (en)
UY (1) UY26086A1 (en)
YU (1) YU13200A (en)
ZA (1) ZA200001586B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (en) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
DE60137273D1 (en) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Process for the preparation of 4-phenoxyquinoline derivatives
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
ES2400339T3 (en) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in the treatment of cancer
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
WO2004080462A1 (en) 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kit KINASE INHIBITOR
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (en) 2003-07-03 2010-12-15 美瑞德生物工程公司 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis
ES2305844T3 (en) 2003-09-16 2008-11-01 Astrazeneca Ab DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE.
PL2210607T3 (en) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CN101337930B (en) 2003-11-11 2010-09-08 卫材R&D管理有限公司 Urea derivative preparation process
GEP20084551B (en) * 2004-05-06 2008-11-25 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
JP4834553B2 (en) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Pharmaceutical composition
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
PL1859793T3 (en) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Novel combinational use of a sulfonamide compound in the treatment of cancer
JP5066446B2 (en) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the effects of angiogenesis inhibitors
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CN101316590B (en) 2005-11-07 2011-08-03 卫材R&D管理有限公司 Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007061130A1 (en) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
KR101472600B1 (en) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
KR20090108086A (en) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition for treatment of pancreatic cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
EP2170844B1 (en) * 2007-02-21 2016-05-04 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
WO2008122776A2 (en) 2007-04-04 2008-10-16 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
EP2183226A2 (en) * 2007-08-23 2010-05-12 Plus Chemicals S.A. Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
JP5399926B2 (en) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination of vascular inhibitor and taxane
US20090269354A1 (en) * 2008-03-28 2009-10-29 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
EP2307386A1 (en) * 2008-07-07 2011-04-13 Plus Chemicals S.A. Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (en) 2008-10-01 2012-04-06 주식회사종근당 ?-3-ethynylphenyl-6,7-bis2-methoxyethoxy-4-quinazolinamine napsylate
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
CN102388024A (en) 2009-01-16 2012-03-21 埃克塞里艾克西斯公司 Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
MX2012014776A (en) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Antitumor agent using compounds having kinase inhibitory effect in combination.
CN103124557A (en) 2010-07-23 2013-05-29 基因里克斯(英国)有限公司 Pure erlotinib
IT1402029B1 (en) * 2010-10-14 2013-08-28 Italiana Sint Spa PROCEDURE FOR THE PREPARATION OF ERLOTINIB
RU2580609C2 (en) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Anticancer therapeutic agent
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
CN102267952B (en) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 Quinazoline compound and preparation method and application thereof
CN103420924B (en) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 A kind of preparation method of Erlotinib hydrochloride crystal form A
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
MX2015004979A (en) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Amorphous form of quinoline derivative, and method for producing same.
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (en) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 Preparation method of hydrochloric acid erlotinib crystal form F
PL3524595T3 (en) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
MX2017010474A (en) 2015-02-25 2017-11-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative.
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
MX2017015896A (en) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Anticancer agent.
CN105884653A (en) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 Erlotinib derivative and preparing method thereof
CN106279585A (en) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 A kind of preparation method of fire-retardant intelligent compact bookshelf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (en) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4-aminoquinazoline derivatives and pharmaceuticals containing them
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
KR100489174B1 (en) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
KR100668412B1 (en) 1998-04-29 2007-01-12 화이자 프로덕츠 인코포레이티드 N-3-ethynylphenylamino-6,7-bis2-methoxyethoxy-4-quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
NO20001648L (en) 2000-10-02
KR100430209B1 (en) 2004-05-03
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
DE60032275T2 (en) 2007-07-12
AU781402B2 (en) 2005-05-19
CA2302965A1 (en) 2000-09-30
EP1044969B1 (en) 2006-12-13
ZA200001586B (en) 2001-10-01
NO20054715L (en) 2000-10-02
HU0001353D0 (en) 2000-06-28
SK287339B6 (en) 2010-07-07
CZ20001155A3 (en) 2001-03-14
IS5411A (en) 2000-10-02
AP1655A (en) 2006-09-01
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
MA25087A1 (en) 2000-10-01
GT200000037A (en) 2001-09-21
JP2000290262A (en) 2000-10-17
EA200000274A3 (en) 2003-02-27
EA200000274A2 (en) 2000-10-30
KR20010014658A (en) 2001-02-26
UA70928C2 (en) 2004-11-15
NZ503683A (en) 2001-09-28
NO324745B1 (en) 2007-12-03
TNSN00064A1 (en) 2005-11-10
RS49836B (en) 2008-08-07
DZ3030A1 (en) 2004-03-27
CN1276370A (en) 2000-12-13
EA005561B1 (en) 2005-04-28
MY136270A (en) 2008-09-30
SK4442000A3 (en) 2000-10-09
NZ512818A (en) 2003-01-31
NO321952B1 (en) 2006-07-24
GEP20022653B (en) 2002-03-25
TW553939B (en) 2003-09-21
KR20020084903A (en) 2002-11-13
CA2427221A1 (en) 2000-09-30
EP1044969A3 (en) 2000-11-29
UY26086A1 (en) 2000-10-31
ES2278578T3 (en) 2007-08-16
CN1699350A (en) 2005-11-23
IL135245A0 (en) 2001-05-20
EE200000255A (en) 2000-12-15
UA80955C2 (en) 2007-11-26
SG115536A1 (en) 2005-10-28
CA2427221C (en) 2008-09-16
US6476040B1 (en) 2002-11-05
JP3420549B2 (en) 2003-06-23
CN100351242C (en) 2007-11-28
JP4074509B2 (en) 2008-04-09
CZ299426B6 (en) 2008-07-23
EA200201244A1 (en) 2003-04-24
JP2003176274A (en) 2003-06-24
AU2005201494B2 (en) 2008-02-07
BR0001486A (en) 2001-05-02
CA2302965C (en) 2004-02-17
KR100430210B1 (en) 2004-05-03
SV2002000047A (en) 2002-01-23
HUP0001353A2 (en) 2001-05-28
BG104278A (en) 2001-08-31
CO5160273A1 (en) 2002-05-30
ATE348098T1 (en) 2007-01-15
PT1044969E (en) 2007-05-31
DE60032275D1 (en) 2007-01-25
OA11335A (en) 2003-12-10
HRP20000182A2 (en) 2001-04-30
EA200201245A1 (en) 2003-04-24
NO20001648D0 (en) 2000-03-30
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
IS2468B (en) 2008-12-15
SG121687A1 (en) 2006-05-26
AP1265A (en) 2004-03-26
ID25427A (en) 2000-10-05
PL339330A1 (en) 2000-10-09
BRPI0001486B1 (en) 2019-01-29
YU13200A (en) 2002-10-18
BRPI0001486B8 (en) 2021-05-25
CR6165A (en) 2008-10-10
PA8491901A1 (en) 2001-12-14
AU2005201494A1 (en) 2005-05-05
AR018705A1 (en) 2001-11-28
TR200000837A2 (en) 2000-11-21
HU227698B1 (en) 2011-12-28
CN1215061C (en) 2005-08-17
EA004654B1 (en) 2004-06-24
BG65194B1 (en) 2007-06-29
HK1029790A1 (en) 2001-04-12
PE20001599A1 (en) 2001-01-18
EA005892B1 (en) 2005-06-30
DK1044969T3 (en) 2007-04-23
HUP0001353A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
EE04589B1 (en) Processes and intermediates for the preparation of anticancer compounds
FI20000564A (en) Process for the preparation of nanolaminates
FI20010154A (en) Process for the preparation of citalopram
NO20015017L (en) Process for the preparation of citalopram
NO20010319D0 (en) Process for the preparation of Citalopram
PT1210113E (en) COMPOUNDS OF COMBINATION VACCINES
NO20042680L (en) Processes for the preparation of O-demethylvenflaxine
EE200100259A (en) Pharmaceutical preparation of moxifloxacin
EE200100536A (en) Process for the preparation of amine-platinum complexes
FI20011622A (en) Process for the preparation of citalopram
NO20016151D0 (en) Preparation of substituted piperidin-4-ones
NO20003454L (en) Process for the preparation of (-) cis-3-hydroxy-1-methyl-4-
NO996432D0 (en) Process for the preparation of 4-substituted-1H-indole-3-glycosamides
PT1175417E (en) SUBSTITUTED COMPOUNDS OF BENZOLACTAMAS
ITMI992048A0 (en) STEREOSELECTIVE PROCEDURE FOR THE PREPARATION OF ENDO-3-AMINOAZAB CYCLOALKANES
DK1177165T3 (en) Process for the preparation of pesticide intermediates
NO20022956D0 (en) Process for the preparation of nitroguanidine
NO20000805L (en) Process for the preparation of organic azides
EE200100333A (en) Process for the preparation of 2-halo-3-nitro-4-aminopyridine and intermediates thereof
NO20020328D0 (en) Process for the preparation of 4-cyano-2-aminomethylthiazole
NO20020327D0 (en) Process for the preparation of 2-aminomethyl-4-cyano-thiazole
NO20003077L (en) Process for the preparation of the chlorobenzoxazole
NO994557D0 (en) Process for the preparation of arylaminotriazolopyridines
NO982975D0 (en) Process for the preparation of phosphate-bound ceramics
NO20002558D0 (en) Process for the preparation of fine-dispersive explosives

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110330